Features of antiplatelet therapy for cerebrovascular diseases in elderly patients
- 作者: Shirokov E.A.1, Glotko V.L.1,2, Levin O.M.3
-
隶属关系:
- Branch of the S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
- The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- National Medical Research Center for High Medical Technologies – the A.A.Vishnevsky Central Military Clinical Hospital Ministry of Defense of the Russian Federation
- 期: 卷 343, 编号 11 (2022)
- 页面: 46-53
- 栏目: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/629741
- DOI: https://doi.org/10.52424/00269050_2022_343_11_46
- ID: 629741
如何引用文章
详细
Ischemic stroke and other diseases of the cardiovascular system associated with atherosclerosis occupy a leading place among the causes of death and permanent disability in older age groups. One of the most effective ways to prevent cardiovascular diseases is antiplatelet therapy. The article discusses the features of antiplatelet therapy in elderly patients. Based on the results of modern studies, new scientific publications and clinical recommendations, data on the efficacy and safety of platelet antiplatelet agents of various pharmacological groups with long-term use in patients of older age groups are summarized.
作者简介
E. Shirokov
Branch of the S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
编辑信件的主要联系方式.
Email: Evg-747747@yandex.ru
профессор
俄罗斯联邦, MoscowV. Glotko
Branch of the S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation; The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: Evg-747747@yandex.ru
доцент, полковник медицинской службы запаса
俄罗斯联邦, Moscow; MoscowO. Levin
National Medical Research Center for High Medical Technologies – the A.A.Vishnevsky Central Military Clinical Hospital Ministry of Defense of the Russian Federation
Email: Evg-747747@yandex.ru
俄罗斯联邦, Krasnogorsk, Moscow Region
参考
- Бурячковская Л.И., Ломакин Н.В., Сумароков А.Б., Доценко Ю.В. Значение особенностей действия антиагрегантов для выбора терапии сосудистого больного // Тромбоз, гемостаз и реология. – 2017. – № 4 (72). – С. 6–13. doi: 10.25555/THR.2017.4.0803
- Здравоохранение в России. 2019: Стат. сб. / Росстат. – М., 2019. – 170 с.
- Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками / Под ред. Л.В.Стаховской. – М., 2017. – 208 с.
- Ломакин Н.В., Сумароков А.Б., Доценко Ю.В. и др. Индивидуальный подход к применению антитромбоцитарной терапии. На что опереться в решении? // Атеротромбоз. – 2017. – № 2. – С. 70–78. doi: 10.21518/2307-1109-2017-2-70-78
- Мачинский П.А., Плотникова Н.А., Ульянкин В.Е. и др. Сравнительная характеристика показателей заболеваемости ишемическим и геморрагическим инсультом в России // Мед. науки. Патологическая анатомия. – 2019. – № 2 (50). – С. 112–131. doi: 10.21685/2072-3032-2019-2-11
- Сумароков А.Б., Широков Е.А., Бурячковская Л.И. Антитромбоцитарная терапия в профилактике ишемического некардиоэмболического инсульта. Основные положения современных рекомендаций. – М., 2015. – 34 с.
- Суслина З.А., Танашян М.М., Домашенко М.А. Индивидуализация антиагрегантной терапии у пациентов с цереброваскулярными заболеваниями // Клин. фармакол. тер. – 2011. – № 5. – С. 70–74.
- Широков Е.А., Симоненко В.Б., Овчинников Ю.В. Транзиторные ишемические атаки и малые инсульты: современные терапевтические стратегии // Леч. врач. – 2020. – № 5. – С. 7–11. doi: 10.26295/OS.2020.56.70.001
- Balint A., Tornyos D., Alaoui O. et al. Network Meta-Analis of Ticagrelor for Stroke prevention in patients at High Risk for Cardiovascular or Cerebrovascular Events // Stroke. – 2021. – Vol. 52, N 9. – P. 2809–2816. doi: 10.1161/STROKEAHA.120.032670
- CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) // Lancet. – 1996. – Vol. 348, Iss. 9038. – P. 1329–1339. doi: 10.1016/s0140-6736(96)09457-3
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in highrisk patients // BMJ. – 2002. – Vol. 324, N 71. – P. 71–86. DOI: org/10.1136/bmj.324.7329.71
- Chen Z.M., Sandercock P., Pan H.C. et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups // Stroke. – 2000. – Vol. 31, N 6. – P. 1240–1249. doi: 10.1161/01.str.31.6.1240
- Cho Y.J., Koo J.S., Park J.M. et al. Factors associated with stroke progression in acute cerebral infarction // Int. J. Stroke. – 2008. – Vol. 3. – P. 405–409.
- Diener H.C., Sacco R., Yusuf S. Steering Committee. PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS) // Cerebrovasc. Dis. – 2007. – Vol. 23, N 5–6. – P. 368–380. doi: 10.1159/000100105
- Greving J.P., Diener H., Reitsma J.B. et al. Antiplatelet Therapy After Noncardioembolic Stroke // Stroke. – 2019. – Vol. 50, N 7. – P. 1812–1818. doi: 10.1161/STROKEAHA.118.024497.
- Johnston S.C., Amarenco P., Denison H. et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA // N. Engl. J. Med. – 2020. – Vol. 383, N 3. – P. 207–217. doi: 10.1056/NEJMoa1916870
- Kennedy J., Hill M.D., Ryckborst K.J. et al. For the FASTER investigators: Fast Assessment of Stroke and Transient Ischemic Attack to prevent Early Recurrence (FASTER): a randomized controlled pilot trial // Lancet Neurol. – 2007. – Vol. 6, N 11. – P. 961–969. doi: 10.1016/S1474-4422(07)70250-8
- Li Z., Wang Y., Zhao X. et al. Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack // J. Am. Heart Assoc. – 2016. – Vol. 5, N 3. – P. e003038. DOI: 10/1161/JAHA.115.003038
- Linxin Li, Catherine A Scott, Peter M. Rothwell. Oxford Vascular Study. Trends in Stroke Incidence in High-Income Countries in the 21st Century Population-Based Study and Systematic Review // Stroke. – 2020. – Vol. 51, N 5. – P. 1372–1380. doi: 10.1161/STROKEAHA. 119.028484
- McHutchison C., Blair G.W., Appleton J.P. et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis // Stroke. – 2020. – Vol. 51, N 8. – P. 2374–2385. doi: 10.1161/STROKEAHA. 120.029454
- Niu P.-P., Guo Z.-N., Jin H. et al. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis // BMJ Open. – 2016. – Vol. 6, N 3. – P. e009013. doi: 10.1136/bmjopen-2015-009013.
- Rothwell P., Algra A., Chen Z. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials // Lancet. – 2016. – Vol. 388, Iss. 10042. – P. 365–375. doi: 10.1016/S0140-6736(16)30468-8
- SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe // Europ. Heart J. – 2021. – Vol. 42, Iss. 25. – P. 2439–2454. doi: 10.1093/eurheart/ehab309
- Shaban A., Monlezun D.J., Rincon N. et al. Safety and Efficacy of Acute Clopidogrel Load in Patients with Moderate and Severe Ischemic Strokes // Stroke Research and Treatment. – 2016. – Vol. 2016, Art. 8915764. DOI: 10/1155/2016/8915764
- Uchiyama S., Amarenco P., Minematsu K., Wong K.S.L. TIA as acute Сerebrovascular Syndrome // Front. Neurol. Neurosci. – 2014. – Vol. 33. – P. 135–146. doi: 10.1159/isbn.978-3-318-02459-3
- Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice // Europ. Heart J. – 2021. – Vol. 42, Iss. 34. – P.3227–3337. doi: 10.1093/eurheartj/ehab484
- Wang Y., Meng A., Wang A. et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of Function Carries with Stroke or TIA // N. Engl. J. Med. – 2021. – Vol 385 (27). – P. 2520–2530. DOI: 10/1056/NEJMoa2111749
- Zurru M., Orzuza G. Epidemiological Aspects of Stroke in Very Old Patients// Cardiovascular and Haematological Disorders-Drug Targets. – 2011. – Vol. 11, N 1. – P. 2–5. doi: 10.2174/187152911795945187